Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 1, 2010, Pages 90-98

  Hardy, Dale ^a   Cormier, Janice N ^b   Xing, Yan ^b   Liu, Chih Chin ^a   Xia, Rui ^a   Du, Xianglin L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Comorbidities; Non small cell lung cancer; Toxicity; Tumor stage; Years of diagnosis

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ACUTE KIDNEY FAILURE; AGED; ANOREXIA; ARTICLE; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BLADDER CANCER; BRAIN DISEASE; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; COGNITIVE DEFECT; COLITIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DELIRIUM; DEMENTIA; DERMATITIS; DIARRHEA; DRUG FATALITY; DRUG FEVER; FATIGUE; FEMALE; GASTROENTERITIS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEMATURIA; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INDUCED HYPOTENSION; INFECTION; LEUKEMIA; LIVER DYSFUNCTION; LUNG EDEMA; LUNG EMBOLISM; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MYOCARDITIS; NAUSEA; NEUTROPENIA; OTOTOXICITY; PAROXYSMAL TACHYCARDIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; PSYCHOSIS; RAYNAUD PHENOMENON; RESPIRATORY FAILURE; RISK FACTOR; SEIZURE; SIDE EFFECT; STOMATITIS; STUPOR; SUDDEN DEATH; THORAX PAIN; THROMBOCYTOPENIA; ADENOCARCINOMA; CANCER REGISTRY; CANCER STAGING; COHORT ANALYSIS; DRUG TOXICITY; FOLLOW UP; INCIDENCE; LARGE CELL CARCINOMA; LUNG TUMOR; METASTASIS; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COHORT STUDIES; DEOXYCYTIDINE; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 84868187801     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c0a128     Document Type: Article

References (25)

1. Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV nonsmall cell lung cancer. Chest 2003;123:226S-243S.
2. Socinski MA, Crowell R, Hensing TE, et al.; American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:277S-289S. (Pubitemid 47502813)
3. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicaretumor registry database. Med Care 1993;31:732-748.
4. Du XL, Chan W, Giordano S, et al. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer 2005;104:913-924.
5. Non-Small Cell Lung Cancer, 2008. Fort Washington, PA: NCCN.org. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines. asp?button-I-Agree. Accessed May 12, 2009.
6. Cunningham J. National Cancer Institute (U.S.). Surveillance Program, SEER Program (National Cancer Institute (U.S.). The SEER Program Code Manual. Revised. Ed. Bethesda, MD: Cancer Statistic Branch, National Cancer Institute, National Institute of Health; 1994.
7. United States, Health Care Financing Administration, Practice Management Information Corporation. HCPCS 1994 National Level II Medicare Codes: HCFA Common Procedure Coding System. Los Angeles, CA: Practice Management Information Corp. (PMIC); 1994.
8. Du X, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. Surveillance, Epidemiology and End Results. J Clin Epidemiol 1999;52:463-470.
9. World Health Organization, WHO Collaborating Centres for Classification of Diseases. International Statistical Classification of Diseases and Related Health Problems. 10th Revised Ed. Geneva: World Health Organization; 1992-1994.
10. Abdi H. The Bonferonni and šidák Corrections For Multiple Comparisons. Encyclopedia of Measurement and Statistics. Thousand Oaks, CA: Sage; 2007. Available at: http://www.utdallas.edu/-herve/Abdi-Bonferroni2007- pretty.pdf.
11. Helbekkmo N, Aasebo U, Sundstrom SH, von Plessen C, Brunsvig PF, Bremnes RM; Norwegian Lung Cancer Study Group. Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer 2008; 62:253-260.
12. Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008;62:85-91.
13. Winton T, Livingston R, Johnson D, et al.; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
14. Maestu I, Munoz J, Gomez-Aldaravi L, et al. Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine. Clin Transl Oncol 2007;9:99-105.
15. Ramlau R, Zatloukal P, Jassem J, et al. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/ vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 2008;26:1886-1892.
16. Ardizzoni A, Boni L, Tiseo M, et al.; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-857.
17. Gebbia V, Galetta D, Caruso M, et al.; Gruppo Oncologico Italia Meridionale. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide-gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003;39:179-189.
18. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-arm cooperative study in Japan. Ann Oncol 2007;18: 317-323.
19. Gebbia V, Galetta D, Lorusso V, et al.; Gruppo Oncologico Italia Meridionale. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). Lung Cancer 2008;61:369-377.
20. Kubota K, Kawahara M, Ogawara M, et al.; Japan Multi-National Trial Organisation. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol. 2008;9:1135-1142.
21. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598.
22. Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-3224.
23. Helbekkmo N, Sundstrom SH, Aasebo U, et al.; Norwegian Lung Cancer Study Group. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007;9:283-289.
24. Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005;6:669-677.
25. American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, et al. American society of clinical oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947.